hLAG3

Fig1. Detection of LAG3 expression by RT-PCR. 

Wild type: only one band at 266 bp with primers 5/6(mLag3);

Heterozygous: one band at 266 bp with primers 5/6(mLAG3) and one band at 150 bp with primers 7/8(hLAG3); 

Abbr. M, DNA marker; HO, homozygous; HE, heterozygous; WT, wild type.

Fig2. Detection of hLAG3 expression on T cells in hLAG3 KI mice.

Note. Splenocytes from C57BL/6 and homozygous hLAG3 mice were stimulated with anti-mCD3 antibody in vitro.

Fig3. In vivo validation of anti-tumor efficacy in a MC38 tumor-bearing model of humanized LAG3 mouse. 

Homozygous humanized LAG3 mice were inoculated with MC38 colon cancer cell lines. After the tumors grew to 50 mm3, the animals were randomly assigned into different groups (n=5). The results showed that the anti-tumor effect was not observed when the antibody targeting human LAG3 was administered alone. However, a significant anti-tumor effect was observed when the antibody targeting human LAG3 was administered together with the anti-PD1 antibody.

Fig4. In vivo validation of anti-tumor efficacy in a MC38 tumorbearing model of humanized LAG3 mouse. 

Homozygous humanized LAG3 mice were inoculated with MC38 colon cancer cell lines. After the tumors grew to 70-80 mm3, the animals were randomly assigned into different groups (n=8). The results showed a significant anti-tumor effect was observed when the antibody targeting human LAG3 was administered together with Tencentriq.